Share on StockTwits

Qiagen N.V. (NASDAQ:QGEN) has been given an average recommendation of “Hold” by the twelve ratings firms that are presently covering the company, ARN reports. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $24.22.

Shares of Qiagen N.V. (NASDAQ:QGEN) opened at 24.72 on Wednesday. Qiagen N.V. has a 52-week low of $19.46 and a 52-week high of $24.83. The stock has a 50-day moving average of $23.77 and a 200-day moving average of $22.5. The company has a market cap of $5.763 billion and a price-to-earnings ratio of 116.16.

Qiagen N.V. (NASDAQ:QGEN) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.22 EPS for the quarter, meeting the Thomson Reuters consensus estimate of $0.22. The company had revenue of $317.40 million for the quarter, compared to the consensus estimate of $317.09 million. During the same quarter in the prior year, the company posted $0.23 earnings per share. The company’s quarterly revenue was up 4.5% on a year-over-year basis. Analysts expect that Qiagen N.V. will post $1.08 EPS for the current fiscal year.

A number of research firms have recently commented on QGEN. Analysts at Wells Fargo & Co. initiated coverage on shares of Qiagen N.V. in a research note on Wednesday. They set a “market perform” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Qiagen N.V. in a research note on Tuesday, July 8th. They now have a $26.00 price target on the stock. Finally, analysts at HSBC upgraded shares of Qiagen N.V. from an “underweight” rating to a “neutral” rating in a research note on Tuesday, May 13th. They now have a $23.33 price target on the stock, up previously from $21.88.

QIAGEN N.V., (NASDAQ:QGEN) is a holding company, which provides sample and assay technologies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.